MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The present invention relates to compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of l...

Full description

Saved in:
Bibliographic Details
Main Authors LOUGHRAN, H. Marie, SCHIRRIPA, Kathy, STACHEL, Shawn, MULHEARN, James, ROECKER, Anthony, BRESLIN, Michael, FRALEY, Mark
Format Patent
LanguageEnglish
French
Published 02.06.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs). La présente invention concerne des composés de formule (I) : et des sels ou promédicaments pharmaceutiquement acceptables de ceux-ci. La présente invention concerne également des compositions comprenant au moins un composé de formule (I), et des procédés d'utilisation des composés de formule (I) pour le traitement ou la prophylaxie de maladies de stockage lysosomal, d'une maladie neurodégénérative, d'une maladie kystique, d'un cancer, ou d'une maladie ou de troubles associés à des niveaux élevés de glucosylcéramide (GLcCer), la glucosylsphingosine (GlcSph) et/ou d'autres glycosphingolipides à base de glucosylcéramide (GSLs).
Bibliography:Application Number: WO2021US59809